Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Non-inferiority, Open-label, Randomized Controlled Study to Evaluate the Immunogenicity and Safety of Comvigen (Bivalent) Vaccine as a Booster Dose in Adults Who Have Received a Previous Booster Dose of an Approved COVID-19 Vaccine

NCT05930730 is registered in ClinicalTrials.gov with Chulalongkorn University as lead sponsor.

NCT NCT05930730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05930730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Non-inferiority, Open-label, Randomized Controlled Study to Evaluate the Immunogenicity and Safety of Comvigen (Bivalent) Vaccine as a Booster Dose in Adults Who Have Received a Previous Booster Dose of an Approved COVID-19 Vaccine
Lead sponsor
Chulalongkorn University
Phase
Phase 2
Overall status
Unknown status
Start date
October 9, 2023
Completion date
February 29, 2024
Enrollment
450 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

immunogenicity of a single dose of bivalent pfizer/bnt vaccine, immunogenicity of a single dose of comvigen vaccine, reactogenicity of a single dose of bivalent pfizer/bnt vaccine, reactogenicity of a single dose of comvigen vaccine, safety of a single dose of bivalent pfizer/bnt vaccine, safety of a single dose of comvigen vaccine